| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/16/2005 | CN1582158A Novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases |
| 02/16/2005 | CN1582156A Methods for treating ocular neovascular diseases |
| 02/16/2005 | CN1582154A Method for treating or prophylaxis of aldo sterone-medicated phthogenic effects in subjwect using epoxy-steroidal aldosterone antagonist |
| 02/16/2005 | CN1582152A composition of estrogen and other hormons with ascorbate, lysine, proline and other substances |
| 02/16/2005 | CN1582149A Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| 02/16/2005 | CN1582146A Methods of inducing ovulation usig non-polypeptide adenosin phosphate level modulator |
| 02/16/2005 | CN1579551A Drug giving-up medicine made-up by non-thebaica medicines |
| 02/16/2005 | CN1579550A Nucleic vaccine for tubercle bacillus |
| 02/16/2005 | CN1579549A Composition medicine for curing acute early-young granulocytic leukemia |
| 02/16/2005 | CN1579379A Allylamine derivative composition and its use |
| 02/16/2005 | CN1579373A Transparent disappearing external administration carrier |
| 02/16/2005 | CN1189479C Use of leptin in inhibition of endothelial cell proliferation |
| 02/16/2005 | CN1189214C Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 02/16/2005 | CN1189211C Therapeutic methods and compsns. for treatment of in paired interpersonal and behavioral disorders |
| 02/16/2005 | CN1189168C Use of (-)-(3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance type 2-diabetes, hyperlipidemia and hyperuricemia |
| 02/16/2005 | CN1189163C Adhesive preparations |
| 02/15/2005 | US6855860 Nonocclusive dressing comprising natural polymer fibers and a synthetic polymer foam layer having a pore-containing surface physically interlocked with the fibers; separation; nonadhesive; easy to manufacture; nontoxic; permeability |
| 02/15/2005 | US6855835 Allomorph of isomer Z hydrochloride of alkylaminofurane derivative |
| 02/15/2005 | US6855829 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease |
| 02/15/2005 | US6855823 Selective iGluR5 receptor antagonists |
| 02/15/2005 | US6855812 P-glycoproteins and uses thereof |
| 02/15/2005 | US6855810 Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof |
| 02/15/2005 | US6855770 Drug delivery compositions and medical devices containing block copolymer |
| 02/15/2005 | US6855736 Molecular target of neurotoxicity |
| 02/15/2005 | US6855733 Formulation and manufacturing process for coenzyme Q10 soft gel capsules |
| 02/15/2005 | US6855712 Combination of benzoquinazoline antifolates and protecting agents |
| 02/15/2005 | US6855693 Peptide for use in the treatment of cell damage caused by ischemia |
| 02/15/2005 | US6855689 Anticancer agents |
| 02/15/2005 | US6855687 Administering to the site in need of cartilage repair a polypeptide having the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gl y-Asp-Ser-Pro-Phe-Val |
| 02/15/2005 | US6855684 Compound B as angiogenic agent in combination with human growth factors |
| 02/15/2005 | US6855532 Gene therapy; drug screening |
| 02/15/2005 | US6855510 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 02/15/2005 | US6855340 Administering an agent that binds or complexes copper such as ammonium tetrathiomolybdate |
| 02/15/2005 | US6855338 Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects |
| 02/15/2005 | US6855310 Aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of acetaminophen, orphenadrine or tramadol. |
| 02/15/2005 | US6854468 Treatment of subnormal bone mineral density |
| 02/15/2005 | CA2119562C Method and compositions for the treatment of cerebral palsy |
| 02/12/2005 | CA2477357A1 Sprayable skin protectant compositions |
| 02/12/2005 | CA2436979A1 Methods for preventing neurological events |
| 02/10/2005 | WO2005012280A1 Alkynyl aryl carboxamides |
| 02/10/2005 | WO2005011734A2 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer |
| 02/10/2005 | WO2005011727A1 Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder |
| 02/10/2005 | WO2005011710A1 Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases |
| 02/10/2005 | WO2005011708A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 02/10/2005 | WO2005011698A1 Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia |
| 02/10/2005 | WO2005011680A1 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 02/10/2005 | WO2005011677A1 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/10/2005 | WO2005011665A1 The use of proglumide for the treatment of emesis |
| 02/10/2005 | WO2005011660A1 Use of vitamin d to down regulate the renin-angiotensin-aldosterone system |
| 02/10/2005 | WO2005011652A2 Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
| 02/10/2005 | WO2005011651A2 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 02/10/2005 | WO2005011637A1 At-use dispersed preparation |
| 02/10/2005 | WO2005011636A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | WO2005011634A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 02/10/2005 | WO2005011616A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011614A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011608A2 PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR |
| 02/10/2005 | WO2005011604A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011603A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011602A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011595A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011594A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011586A2 Treatment and preventi0n of cardiovascular events |
| 02/10/2005 | WO2005011580A2 Compositions and methods for herpes simplex prophylaxis and treatment |
| 02/10/2005 | WO2005011572A2 Combination of drugs for the treatment of neoplasms |
| 02/10/2005 | WO2005011400A1 Supplement preparation |
| 02/10/2005 | WO2005004893A3 Inhibition of stress-induced ligand-dependent egfr activation |
| 02/10/2005 | WO2004110415A3 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| 02/10/2005 | WO2004105756A3 Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| 02/10/2005 | WO2004098612A3 Calcitriol analogs of uses thereof |
| 02/10/2005 | WO2004098564A3 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
| 02/10/2005 | WO2004093856A3 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia |
| 02/10/2005 | WO2004037207A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 02/10/2005 | WO2004032826A8 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/10/2005 | WO2003050295A3 Assays and implements for determining and modulating hsp90 binding activity |
| 02/10/2005 | WO2002064626A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 02/10/2005 | WO2002020718A3 Osteoclast-associated receptor |
| 02/10/2005 | US20050034179 Transgenic animal cell which express tumor necrosis factor receptor for use in identifying agents for treatment of diabetes and inflammatory bowel disease |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033261 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 02/10/2005 | US20050033059 Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| 02/10/2005 | US20050033034 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 02/10/2005 | US20050033026 Immunoconjugates for the treatment of tumours |
| 02/10/2005 | US20050033018 Receptors and membrane-associated proteins |
| 02/10/2005 | US20050033017 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/10/2005 | US20050032914 Lutein/zeaxanthin for glare protection |
| 02/10/2005 | US20050032904 Such as terbinafine, butenafine and naftifine; use treating cancer; combination with other chemotherapeutic agents such as nocodazole |
| 02/10/2005 | US20050032899 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
| 02/10/2005 | US20050032895 Medicament for the treatment of viral skin and tumour diseases |
| 02/10/2005 | US20050032893 For topical administration; (N,N-dimethylamino)isopropyl propylene glycol heptadecanoate for example; penetration enhancers have hydrophobic fatty acyl group and hydrophilic dimethylamino and alkylene glycol diester groups |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032882 Botanical extract compositions and methods of use |
| 02/10/2005 | US20050032878 Peroxisome proliferator activated compound of fenofibrate, ciprofibrate, clofibrate, gemifibrozil and/or bezafibrate; and pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, cerivastatin, pravastatin and/or mixtures; and polyglycolized glyceride; dissolving, bioavailability |
| 02/10/2005 | US20050032866 Administering N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or salt as antiarrhythmia agent |
| 02/10/2005 | US20050032852 1-(N-substituted sulfonamido),4-(substituted isooxazoly-4-yl)benzenes, e.g., N-ethyl-4-(5-methyl-3-phenylisoxazol-4-yl)-N-propionylbenzenesulfonamide; side effect reduction; solubility; stability; bioavailability, i.e., readily penetrate membranes; non-steroidal antiinflammatory agents; analgesics |
| 02/10/2005 | US20050032843 Dopamine D1, D2, D3, and D4 receptor agonist such as pramipexole in combination with a second active substance selected from D1, D2, D3, and D4 receptor agonists, anorectics, lipase inhibitors and sympathomimetics; for treating overweight or obesity or type 2 diabetes |
| 02/10/2005 | US20050032841 Enzyme inhibitors of ceramide glucosyltransferase or agents capable of increasing the rate of neuronal glycolipid degradation in treating of mucopolysaccharidosis diseases; e.g., N-butyldeoxynojirimycin and other imino sugars and genetic approaches; synergistic effect on activity of glucocerebrosidase |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032817 Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung |
| 02/10/2005 | US20050032815 Preventing dermatitis in a human by administering a composition consisting of therapeutically effective amounts of optically pure (-) cetirizine or salt thereof, and a leukotriene inhibitor or salt thereof; synergistic mixture; also useful as asthma treatment |